Pomegranate Health
Pomegranate Health is a podcast about the culture of medicine. You'll hear clinicians, researchers and advocates discuss all aspects of professionalism and quality improvement in healthcare. This includes clinical ethics, diagnostic bias, better communication and more equitable systems. For a sampler of these diverse themes of professional practice take a listen to Episode 132 and Episode 125.
If RACP is your CPD home, you can log time spent listening to each episode with the "Add activity to MyCPD" button. And if you're a Basic Physician Trainee, the [Case Report] series might help you prepare for your long case clinical exams.
This is also the home of [IMJ On-Air], featuring authors from the Internal Medicine Journal sharing their latest research. Meanwhile, the [Journal Club] episodes give RACP members a place to talk through their research published in other academic journals.
Feel free to send feedback and suggestions by email at podcast@racp.edu.au.
Pomegranate Health
Ep121: Precision oncology explained
Use Left/Right to seek, Home/End to jump to start or end. Hold shift to jump forward or backward.
The genomic understanding of cancer has transformed a tissue-based classification model that had been dominant for 150 years or more. The last three decades have seen highly targeted therapies developed at blistering pace, and unprecedented improvements in patient outcomes.
To date, these advances have been focused on more common cancers. The financing model for drug development means that rare cancers get overlooked, given the small pool of potential buyers relative to the costs and risks of investment.
However, the molecular targets characterised in more common cancers are often found in cancers of a different histotype. As such, precision therapies will sometimes have tissue-agnostic efficacy and offer a lifeline for patients with neglected diseases or cancers of unknown origin.
Professor David Thomas has founded an NGO called Omico to enable such patients to undergo profiling for hundreds of potential molecular targets. In this interview he explains the rationale for the most promising pan cancer therapies, and in the next episode we discuss changes to the regulatory and funding model required to sustain this screening program.
Guest
Prof David Thomas FRACP PhD (Director, Centre for Molecular Oncology UNSW; Founder and Chief of Science, Omico)
Professor Thomas or Omico have received grants, consultancies or research support from Roche, Astra Zeneca, Pfizer, Eisai, Illumina, Beigene , Elevation Oncology, RedX Pharmaceuticals, SunPharma , Bayer, George Clinical, Novotech , Merck Sharpe and Dohme, Boehringer Ingelheim, Hummingbird, Microba , BioTessellate , PMV Pharma, Australian Unity and Foundation Medicine.
Production
Produced by Mic Cavazzini DPhil. Music licenced from Epidemic Sound includes ‘the Orchard’ by Jakob Ahlbom; ‘Dusty Electronics’ and ‘Pulse Voyage’ by Chill Cole; ‘Tam’ by LJ Kruzer. ‘See you soon’ and ‘Going Undercover’ by Borrtex provided courtesy of FreeMusicArchive. Image by filo licenced through Getty Images.
Editorial feedback was kindly provided by RACP physicians Nichola Ball, Stephen Bacchi, Aafreen Khalid, Simeon Wong, Maansi Arora and Aidan Tan.
Please visit the Pomegranate Health web page for a transcript and supporting references.Login to MyCPD to record listening and reading as a prefilled learning activity. Subscribe to new episode email alerts or search for ‘Pomegranate Health’ in Apple Podcasts, Spotify,Castbox or any podcasting app.